In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Viking Therapeutics Inc.

www.vikingtherapeutics.com

Latest From Viking Therapeutics Inc.

CymaBay Alters NASH Hypothesis After Phase IIb Failure In Hepatic Fat Reduction

Firm points to liver biomarker findings, saying they may yield clear liver benefit at 52 weeks. Both CymaBay's and Genfit's stock prices fell as investors wondered about broader read-through for the PPAR agonist class.

Liver & Hepatic Clinical Trials

NASH News & Notes From The European Liver Meeting

Non-alcoholic steatohepatitis (NASH) was a focal point of EASL’s conference. Madrigal becomes the fifth company into Phase III in NASH, but Viking’s competing THR agonist is progressing also.

Liver & Hepatic Research & Development

In NASH, Gilead Swung For The Fences And Struck Out Again

Gilead took a risky approach with selonsertib in NASH, pursuing a tough liver fibrosis benefit and failing, continuing a trend of disappointments outside of its antiviral franchises. Analysts don’t expect the second Phase III study in less-sick patients to succeed either.

Clinical Trials Research & Development

Madrigal Cements Case For Hepatic Fat Reduction, Other NASH Benefits With MGL-3196

Madrigal’s selective THR beta agonist continues to demonstrate hepatic fat-lowering abilities in 36-week data, along with lipid-lowering characteristics. The company hopes to initiate a Phase III study in early 2019.

Liver & Hepatic Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Metabolic Disorders
  • Musculoskeletal & Connective Tissue Disorders
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Viking Therapeutics Inc.
  • Senior Management
  • Brian Lian, PhD, Pres. & CEO
    Greg Zante, VP, Fin. & Operations
    Hiroko Masamune, PhD, Chief Dev. Officer
    Amy Broidrick, SVP, Corp. Dev.
  • Contact Info
  • Viking Therapeutics Inc.
    Phone: (858) 704-4660
    12340 El Camino Real
    Ste. 250
    San Diego, CA 92130
    USA
UsernamePublicRestriction

Register